(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy … Continued
By Annie Ellis: On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Click plus sign to read more.
By Annie Ellis On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the … Continued
(September 21, 2015) A small study found that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer. The phase II … Continued
Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the … Continued
(9/11/15) By Alan D. D’Andrea, MD, Dana-Farber Cancer Institute and Harvard Medical School, and Elizabeth M. Swisher, MD, University of Washington September is Ovarian Cancer Awareness Month, when we scientists … Continued
The largest private funder of ovarian cancer research awarded $6.3 million in grants while also launching new events and partnerships (September 11, 2015) –Ovarian Cancer Research Fund (OCRF), has awarded … Continued
Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer. September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on.
(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a … Continued
(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel … Continued
(August 19, 2015) Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the … Continued
(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By … Continued
Get email updates about research news, action alerts, and ways to join the fight.
